Predicting Feasibility and Characterizing Performance of extended-release Formulations Using Physiologically Based Pharmacokinetic Modeling

• Raoof A , MoriartyD, BraydenDet al. Comparison of methodologies for evaluating regional intestinal permeability. In: In Vitro–In Vivo Correlations. Young D, Devane JG, Butler J(Eds). Plenum, NY, USA (1997).
   Google Scholar
• Fagerholm U , LindahlA, LennernäsH. Regional intestinal permeability differences in rats of compounds with different physicochemical properties and transport mechanisms. J. Pharm. Pharmacol.49, 687–690 (1997).
   PubMed Web of Science ®Google Scholar
• Ungell A -L, Nylander S, Bergstrand S, Sjöberg Å, Lennernäs H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci.87, 360–366 (1998).
   PubMed Web of Science ®Google Scholar
• Berggren S , Lennernauml;sP, EkelundM, WeströmB, HoogstraateJ, LennernäsH. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. J. Pharm. Pharmacol.55, 963–972 (2003).
   PubMed Web of Science ®Google Scholar
• Amidon GL , Lennernäs,H, Shah,VP, Crison,JR. A theoretical basis for a biopharmaceutic drug classification, the correlation of in vitro drug dissolution and in vivo bioavailability. Pharm. Res.12, 413–420 (1995).
   PubMed Web of Science ®Google Scholar
• Tannergren C , BergendalA, LennernäsH, AbrahamssonB. Toward an increasing understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol. Pharm.6, 60–73 (2009).
   PubMed Web of Science ®Google Scholar
• Winkle H . Implementing quality by design. Presented at: PDA/FDA Joint Regulatory Conference. Washington, DC, USA, 24–28 September 2007.
   Google Scholar
• US FDA. Guidance for Industry. Q8(R2) Pharmaceutical Development. Department of Human and Human Services, Silver Spring, MD, USA (2009).
   Google Scholar
• US FDA. Guidance for Industry Q10 Quality Systems. Department of Health and Human Services, Silver Spring, MD, USA (2009).
   Google Scholar
• Selen A , CruañesMT, MüllertzAet al. Meeting report. Applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit. AAPS J. 12, 465–472. (2010).
   PubMedGoogle Scholar
• Sinko PJ , LeesmanGD, AmidonGL. Predicting fraction dose absorbed in humans using a mass balance approach. Pharm. Res.8, 979–988 (1991).
   PubMed Web of Science ®Google Scholar
• Jamei M , TurnerD, YangJet al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11, 225–237 (2009).
   PubMed Web of Science ®Google Scholar
• Agoram B , WoltoszWS, BolgerMB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Del. Rev.50, S41–S67 (2001).
   PubMed Web of Science ®Google Scholar
• Parrott N , LavéT. Applications of physiologically based absorption models in drug discovery and development. Mol. Pharm.5, 760–775 (2008).
   PubMed Web of Science ®Google Scholar
• Parrott N , LavéT. Computer models for predicting drug absorption. In: Oral Drug Absorption, Prediction and Assessment, second edition. Dressman JB, Reppas C (Eds). Informa Healthcare, NY, USA (2010).
   Google Scholar
• Poulin P , JonesRDO, JonesHMet al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration- time profiles in human by using the physiologically-based pharmacokinetic modelling approach. J. Pharm. Sci. 100, 4127–4157 (2011).
   PubMed Web of Science ®Google Scholar
• Rowland M , PeckC, TuckerG. Physiologically-based pharmacokinetics in drug development and regulatory science. Ann. Rev. Pharm. Tox.51, 45–73 (2011).
   PubMed Web of Science ®Google Scholar
• Sugano K . Introduction to computational oral absorption simulation. Exp. Opin. Drug Metab. Toxicol.5, 259–293 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang X , LionbergerRA, DavitBM, YuLX. Utility of physiologically based absorption modelling in implementing quality by design in drug development. AAPS J.13, 59–71 (2011).
   PubMed Web of Science ®Google Scholar
• Bolger MB , FraczkiewiczR, LukacovaV. Simulation of absorption, metabolism and bioavailability. In: Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability. Methods and Principles in Medicinal Chemistry (2nd Edition). van der Waterbeemd H, Lennernäs H, Artusson P (Eds). Wiley-VCH, Weinheim, Germany (2009).
   Google Scholar
• Lukacova V , WoltoszWS, BolgerMB. Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release and intravenous data. AAPS J.11, 323–334. (2009).
   PubMed Web of Science ®Google Scholar
• Jiang W , KimS, ZhangXet al. The role of predictive biopharmaceutical modelling and simulation in drug development and regulatory evaluation. Int. J. Pharm. 418, 151–160 (2011).
   PubMed Web of Science ®Google Scholar
• Watson KJ , DavisJ, JonesHM. Application of physiologically based pharmacokinetic modelling to understanding the clinical pharmacokinetics of UK-369003. Drug Met. Disp.39, 1203–1213 (2011).
   PubMed Web of Science ®Google Scholar
• Reddy MD , ConnorA, BrennanBJet al. Physiological modelling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. Biopharm. Drug Disp. 32, 261–275 (2011).
   PubMed Web of Science ®Google Scholar
• Connor A , KingG, JonesK. Evaluation of human regional bioavailability to assess whether modified release development is feasible. Proc. AAPS Annual Meeting9(Suppl. 2), 724 (2007).
   Google Scholar
• Zhu L , ChangI, RubinoCet al. Exposure–response analysis of an oral HIV attachment inhibitor BMS-663068 following 8 days of monotherapy in HIV-infected patients. Presented at: 12th International Workshop on Clinical Pharmacotherapy of HIV Therapy. Miami, FL, USA, 13–15 April 2011.
   Google Scholar
• Heimbach T , Oh D-M, Li LY, Rodríguez-Hornedo N, Garcia G, Fleisher D. Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs. Int. J. Pharm.261, 81–92 (2003).
   PubMedGoogle Scholar
• Brown JR . Challenges and solutions in the delivery of a prodrug in an oral extended-release delivery system. Presented at: 9th Annual SMI conference on Controlled Release. London, UK, 28–29 March 2012.
   Google Scholar
• Marathe P , GreenD, BarbhaiyaR, WenY, CrisonJR Timmins P. Use of a pharmacokinetic absorption model and site of absorption studies to design modified release formulations for BCS3 compounds. Presented at: 3rd PharmSciFair meeting. Prague, Czech Republic, 13–17 June 2011.
   Google Scholar
• Bergstrand M , SöderlindE, ErikssonUG, WeitschiesW, KarlssonMO. A semi-mechanistic modelling strategy to link in vitro and in vivo drug release for modified release formulations. Pharm. Res.29, 695–706 (2012).
   PubMed Web of Science ®Google Scholar
• Bergstrand M , SönderlindE, ErikssonUG, WeitschiesW, KarlssonMO. A semi-mechanistic modelling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations. Pharm. Res.29, 574–584 (2012).
   PubMed Web of Science ®Google Scholar
• Yu LX , AmidonGL. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm.186, 119–125 (1999).
   PubMed Web of Science ®Google Scholar
• Corrigan O . The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. In: In Vitro–In Vivo Correlations. Young D, Devane JG, Butler J (Eds). Plenum, NY, USA (1997).
   Google Scholar
• Edwards CA . Anatomical and physiological basis: physiological factors influencing drug absorption. In: Colonic Drug Absorption and Metabolism. Marcel Dekker, NY, USA (1993).
   Google Scholar
• Lennernäs H . Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr. Drug Metab.8, 645–657 (2007).
   PubMed Web of Science ®Google Scholar
• Huang S -M, Rowland M. The role of physiologically based pharmacokinetic modelling in regulatory review. Clin. Pharm. Ther.91, 542–549 (2012).
   PubMed Web of Science ®Google Scholar
• Jönsson S , HenningssonA, EdholmM, SalmonsonT. Role of modelling and simulation: a European regulatory perspective. Clin. Pharmacokinet.51, 69–76 (2012).
   PubMed Web of Science ®Google Scholar
• Grillo JA , ZhaoP, BullockJet al. Utiltiy of physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice. Biopharm. Drug Dispos. 33, 99–110 (2012).
   PubMed Web of Science ®Google Scholar
• Lalonde RL , KowalskiKG, HutmacherMMet al. Model-based drug development. Clin. Pharmacol. Ther. 982, 21–32 (2007).
   Google Scholar
• Simulations Plus, Inc. GastroPlus User‘s Manual (Version 7.0). Lancaster, CA, USA (2010).
   Google Scholar

Website

• US FDA. Briefing information for the April 13 2010 meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee. www.fda.gov/downloads/AdvisoryCommitees/CommitteesMeetingMaterials/Drugs/oryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM207955.pdf
   Google Scholar